VHIRhttp://www.vhir.org/salapremsa/noticies/noticies_paginacio.asp?page=1&mv1=5&mv2=3es-esIRHUV15The European Medicines Agency grants the "orphan drug" designation to a viral vector tested in VHIR (19/09/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=193&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0193\2014_0193_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The viral vector is the first one approved by the European Medicines Agency (EMA) for the treatment of mitochondrial neurogastrointestinal encephalomyopathy (MNGIE), a rare and lethal autosomal recessive hereditary disease caused by defects in nucleoside metabolism. The project is the result of a collaboration between the Neuromuscular and Mitochondrial Pathology Group, led by Dr. Ramon Martí, and the Gene and Cell Therapy Group, led by Dr. Jordi Barquinero.&nbsp; The disease is caused by mutations in the TYMP gene that encodes for thymidine phosphorylase, an enzyme involved in pyrimidine metabolism. A loss of this enzyme´s activity results in the accumulation of thymidine and deoxyuridine in the organism, which is particularly toxic to mitochondrial DNA synthesis. Disease symptoms generally appear in the second decade of life, with alterations in gastrointestinal motility and neurological defects, leading to progressive cachexia. To date, safe and efficient long-term treatments for the disease are lacking. Bone marrow transplantation from a healthy donor is the only treatment that has shown a positive effect, but the use of this procedure is extremely limited by the lack of donors and the high mortality rates observed in these patients.&nbsp; Using a mouse model of the disease, the VHIR researchers showed a potent effect when transferring bone marrow cells transduced with a viral vector containing a functional version of the TMYP gene. “However” Dr. Barquinero points out “given the high toxicity of bone marrow transplantation in MNGIE patients we decided to test a safer approach based on a liver-specific vector that had been successfully used in patients with hemophilia”. The researchers say that results obtained with the AAV-TYMP vector in the animal model, in collaboration with Dr. M. Zeviani from the Medical Research Council, Cambridge, are even more encouraging, as one single i.v. injection of the vector permanently corrects the metabolic defect in mice. The next step is to translate these results to the clinics. The designation of the vector as an orphan drug by the EMA will now allow the VHIR researchers to build an international consortium to apply for the European Program Horizon 2020 call on New Therapies for Rare Diseases. The consortium, whose main goal is to design and conduct a clinical trial, will be coordinated by Dr. Martí and includes other European groups, as well as the laboratory of Dr. M. Hirano, one of the leading experts in the disease, at the Columbia University in New York, and Genethon, a french non profit organis ation that will produce the vector in GMP conditions for its use in the clinics.&nbsp;&nbsp;&nbsp;&nbsp; </td></tr></table>comunica@vhir.org (VHIR)Fri, 19 Sep 2014 00:00:00 GMTVHIR is holding a Multiple Myeloma patient education event (18/09/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=191&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0191\2014_0191_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Multiple myeloma is a cancer that starts at the bone marrow blood cells. In the last few years, important progress has been made in its treatment thanks to research, offering new hope to patients and their families. To report on this advances Vall d’Hebron Institute of Research (VHIR), together with online cancer patients community Patient Power and the collaboration of the Catalan Institute of Oncology (ICO), is holding an educational event for myeloma patients. The event will take place on Saturday October 11 at Vall d’Hebron Teaching Pavillion from 10 AM. Top researchers will speak at the event, such as Dr Mercè Gironella, Hematology doctor and head of Myeloma research at Hospital Universitary Vall d'Hebron and Dr Francesc Bosch, Head of Onco-Hematology and Experimental Hematology Research Group in the VHIR. The goal is that myeloma patients learn about what is being done in research and they can exchange views with other patients and researchers. An oncology nurse and a psycho-oncologist will also advice patients on how to deal with treatment side effects and how to manage emotions during the cancer journey. The researchers that will speak at the event are: - Dr Mercè Gironella. Hematology doctor and head of Myeloma research at Hospital Universitari Vall d'Hebron since 2010. - Dr Francesc Bosch. Head of Onco-Hematology and Experimental Hematology Research Group in VHIR. <span style=" font-size: 8pt; font-family: 'Verdana', 'Geneva', sans-serif; font-style:</td></tr></table>comunica@vhir.org (VHIR)Thu, 18 Sep 2014 00:00:00 GMTThe series of conferences on Rare Diseases arrives at Madrid (17/09/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=189&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0189\2014_0189_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> With Dr. Llera this Wednesday, September 17, resume the first series of conferences on rare diseases organized by the Vall d’Hebron Institute of Research (VHIR). Also, with this seminar, the cicle arrives at Madrid, as by now all have taken place in Barcelona. Dr. Llera’s conference, Optimizing the investigation processes on rare diseases and orphan drugs, is the seventh seminar programmed about rare diseases, and is 8 out of the 12 seminars that the Fundación Areces sponsors that will take place in Barcelona and Madrid, coinciding with the 20th anniversary of the Institute. The next seminar will be in Barcelona, on September 23, with Dr. Jordi Llinares, Head of Department-Product Development Scientific Support European Medicines Ageny, London (United Kingdom). And the next event in Madrid will be on October 29 with Dr. Ségolène Aymé, chair of the Topical Advisory Group for Rare Diseases Orphanet and director of the Insitut Nationale de la Santé et de la Recherche Médical (France). Until now, the hospital has hosted half of the seminars, with Dr. Ignacio Burgos, driver and coordinator of the rare diseases workshop at the Senate; Dr. Alastair Kent, director at the Genetic Alliance UK; Dr. Christoph Klein, Physician-in-Chief and Chairman at the Dr. von Hauner Children’s Hospital in Munich (Germany); Dr. Paul Lasko<span style=" font-size: 8pt; font-family: 'Verdana', 'Geneva', sans-serif; font-style: normal; font-weight: normal; color: #555555; background-color: transparent; text-deco</td></tr></table>comunica@vhir.org (VHIR)Wed, 17 Sep 2014 00:00:00 GMTVall d'Hebron establishes international basis for the management of respiratory infections in critical patients (16/09/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=188&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0188\2014_0188_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Dr. Jordi Rello, head of the Intensive Care Service and the Clinical Research/Innovation in Pneumonia &amp; Sepsis (CRIPS) group at Vall d’Hebron Institute of Research (VHIR), and head of the Intensive Care Service at the Hospital Universitari Vall d’Hebron, has set the foundations for a new model to guide the management of intensive care patients that have developed respiratory infections associated to mechanical ventilation. The conclusions of the study have been published at The Lancet Respiratoy Medicine and have been presented recently at the ERS International Congress , held in Munich, Germany. The researcher from VHIR and the Centro de Investigación en Red de Enfermedades Respiratorias (CIBERES), together with a researcher from the Hospital de Clinicas in Porto Alegre, Brasil, and a researcher from Brisbaine, Australia, has revised nearly a thousand articles published the last decade about pneumonia and tracheobronchitis caused by mechanical ventilation received in the ICU. Thanks to this basis, according to Dr. Rello, “the study establishes a new paradigm with the progress made the last 10 years that will guide a new approach to the managing of these patients in the next 5 or 10 years”. The infection of the airways is the main cause of antibiotic administration at the ICU and it usually presents in the form of severe sepsis or septic shock in patients that receive mechanical ventilation. The study shows that nearly 30 per cent of these infections evolve to pneumonia and the 70 per cent in tracheobronchitis, but finds that their differentiation is difficult because it depends on a lot of variables. The article describes for the first time the differences between the 8 main pathogens and shows how many days it takes pneumonia to appear after intubation, based on data not published of the largest European collaboration network in the study of this disease, the EUVAP. </td></tr></table>comunica@vhir.org (VHIR)Tue, 16 Sep 2014 00:00:00 GMTDr. Elisa Carenza is awarded the "Dr. Ramón Ríos prize" (15/09/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=187&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0187\2014_0187_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Dr. Carenza received the award, worth 2.500 euro, in the category of first author under 30 of the best research work. The research work is directed by Dr. Anna Rosell, from the research group on Neurovascular diseases at theVall d’Hebron Institut de Recerca (VHIR), and Dr. Anna Roig, from the Institut de Ciència dels Materials del CSIC (ICMAB-CSIC), and was published this past January in the journal “Nanomedicine: Nanotechnology, Biology and Medicine”. The awarded and first author of the study, Dr. Elisa Carenza, did her doctorate with Drs. Rosell and Roig at VHIR and ICMAB-CSIC, under an agreement between the two institutions. The study focuses on the potential use of endothelial progenitor cells (EPCs) in strategies of neurological repair. For this purpose, they use a new technology based on the use of a external magnetic device to guide the EPCs, previously marked with iron oxide nanoparticles, to the brain. The authors show that the marked cells are viable and functional, and that they arrive successfully to the zones of interest on the brain when they are injected intravenously in model mice. The study concludes that is a secure and effective strategy to guide cells to specific zones of the brain, and it opens a new path on cell therapies driven to the regeneration of nerve tissue. The Foltra Foundation is a project that has the objective of helping physical and intellectual rehabilitation of the patients with neurological damage, central or peripheral, congenital or acquired, once the first phase of hospital assistance is over. The jury is formed by national and international Scientifics, experts on the fields of restorative neurogenesis and neuronal plasticity. The prize-giving ceremony will be announced soon and it is going to be during a scientific meeting taking place at the Foundation. </td></tr></table>comunica@vhir.org (VHIR)Mon, 15 Sep 2014 00:00:00 GMTThis September 21, run 5 km for hepatic cancer at Horta (15/09/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=180&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0180\2014_0180_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> 5 days to go... It's coming the closing date for registration for the V Cursa Nick Sport d'Horta, the charity race, that this year is dedicated to hepatic cancer at the Vall d’Hebron Institut de Recerca (VHIR). Register individually or in teams of two and run 5km for hepatic cancer. María José Moscoso is the promoter of the race and it’s been 9 months since she got a liver transplant at Vall d’Hebron, after she was diagnosed with hepatic cancer. Today the race was presented with the presence of Francina Vila representing the City Hall, and Dr. Ramon Charco, head of the digestive transplants group at VHIR. “I feel that I must help all the people who have been with me and the Catalan public system of health”, said María José, that admitted that “I consider my duty to compensate somehow all the things that the doctors have done to keep me alive and healthy”. This is the reason why the last two years the charity race has dedicated all funds to the research at VHIR; the goal is to collect more funds than last year that raised nearly 5,000 euro. The main novelty for this year event, next September 21, is a free special race for young people and children with Down syndrome or any other disability that will join the race in the last 1.5km. </td></tr></table>comunica@vhir.org (VHIR)Mon, 15 Sep 2014 00:00:00 GMTThe campaign 'Migraine, get it out of the closet' aims to give visibility to those who suffer this disease (12/09/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=186&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0186\2014_0186_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Coinciding with the "Migraine awareness week", the Vall d’Hebron Institut de Recerca (VHIR) promotes the campaign “Migraine, get it out of the closet” with the aim of identifying who suffers this disease to help building awareness to society about its importance. “The patients suffering from migraine must know they are not alone, that there is a lot of people like them suffering from this disease, and together they can make their problem more known and thanks to this be able to improve their current quality of life and their future, thanks to investigation”, ensures Dr. Patricia Pozo, leader of the research group on Headache &amp; neurological pain at VHIR. In Spain, approximately 4 million people (12.5 per cent of the population) suffer from migraine. Most of them do it in silence. Migraine affects the quality of life of individuals and has huge social and economic impact (six days time off work and eight of underperformance each year per affected), and also on health care (one third of the neurological consults are because of this disease). Telling the story of the patients suffering from migraine and losing the fear of being recognized for it can be useful, not only for stopping being invisible, but also to raise awareness about the importance of this collective and their needs. </td></tr></table>comunica@vhir.org (VHIR)Fri, 12 Sep 2014 00:00:00 GMTThe research behind the ice bucket (09/09/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=185&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0185\2014_0185_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Ice Bucket Challenge has been, without a doubt, the viral of the summer and it has become a worldwide solidarity campaign thanks to the boost it has received by the social media. Anonymous people and, particularly, celebrities have made the initiative spread really fast. But, besides raising money all over the world, it has brought into the open the disease behind the ALS acronym, Amyotrophic lateral sclerosis. The Vall d’Hebron Institut de Recerca (VHIR) is a leading center in ALS research. The group of Peripheral nervous system, led by Dr. Josep Gámez, is currently working on three different research lines dedicated to the study of molecular mechanisms and genetic mutations of the disease. The group is also part of ALSUntangled, an international network of clinical experts with the aim of offering alternative or off-label ALS treatments. Besides the research team, the Vall d’Hebron University Hospital has an interdisciplinary unit devoted to the care of ALS patients, which serve nearly 100 out of the 400 affected that are in Catalunya. The cause of ALS is unknown and there is no cure or treatment available. It is a debilitating disease characterized by the loss of motor neurons which cause rapidly progressive weakness, muscle atrophy and the death of the patients by breathing failure. These days we have wanted to get to know better the research that is taking place at VHIR on ALS, and the stories behind some patients we treat at our hospital. Patients, assistants and researchers have positively appraised the ice bucket initiative that has been useful to raise awareness about the disease they suffer or dedicate great part of their time to. Now it’s time to keep fighting so that the disease and ALS patients are not forgotten, and because everyone that has become aware and want to collaborate does it also for this research. At VHIR you can make donations through the platform yoinvestigo.org, for research in general and also specifically for ALS research line. </td></tr></table>comunica@vhir.org (VHIR)Tue, 9 Sep 2014 00:00:00 GMTThe Gynecological Oncology group is awarded a grant for investigating endometrial cancer (05/09/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=182&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0182\2014_0182_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The program rewards projects that develop new technologies and promote the application of new ideas and technologies arising from collaborations between academia and industry. The other participants in the project are the Oncology-Pathology group from the IRB of Lleida, led by Dr. Xavier Matias-Guiu, and the companies ForMune and Althia. The Project, awarded a total of 650.769,80€ of which 107.350€ are for the VHIR group, focuses on the prediction of endometrial cancer recurrence and the design of new therapeutic strategies.&nbsp; The main goal is to find a method to determine the risk of disease recurrence, since identification of patients at high risk is critical for deciding the best therapeutic strategy and for a more rational design of clinical trials.&nbsp; 80% of patients with endometrial cancer have a good prognosis. Even so, it remains among the 10 most fatal cancers for women in developing countries due to its high incidence. Mortality is directly linked to the recurrence risk. Improving global survival and decreasing recurrence depends on the search of reliable biomarkers that permit identification of patients that may relapse. The project proposes to develop a predictive method based on the expression of the ANXA2 protein, and to use it as a tool for optimal categorization of patients susceptible to receiving treatment.&nbsp;&nbsp; Other research groups from VHIR have also received funds from this program. They include the Rheumatology team, led by Dr. Sara Marsal, in the Systemic Diseases group, and the Peripheral Nervous System group, led by Dr. Josep Gamez. The latter received funding for two projects within the same call, something unusual for such a highly competitive program. In all, VHIR has obtained 471.921€ for 4 different research projects in the 2014 call.&nbsp; </td></tr></table>comunica@vhir.org (VHIR)Fri, 5 Sep 2014 00:00:00 GMTLast places available for the Master's Degree in Translational Biomedical Research (02/09/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2013&num=276&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2013\2013_0276\2013_0276_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Vall d’Hebron Institute of Research will start on October 2014 the first edition of the new Master in Translational Biomedical Research, affiliated to Universitat Autònoma de Barcelona. The aim of the program is to generate excellent young researchers by providing them with the necessary combination of scientific and medical knowledge and skills to contribute successfully to the future of translational medical research. Since pre-registration opened last February, there have been two selection and admission processes for the first students on the first edition of the program. The last pre-registration period is open until September 30, 2014, and students can apply for one of the 10 grants that the VHIR offers. The Master’s Degree in Translational Biomedical Research is a unique program, for the environment, and because it addresses the world of biomedical research from the relationship between clinicians and researchers, for a more translational biomedical research. The main feature of this master programme is that takes place in a research institute recognized as Instituto de Investigación Sanitaria by the Instituto de Salud Carlos III, an organism depending of the Spanish Government. All the classes will be given at VHIR during the first semester by basic, clinical researchers and medical doctors who are in continuous contact with patients. The second semester will be devoted to the the master’s project and the practice internship that could be carried out in one of the 60 research groups from the 10 research areas of the Institute. <span st</td></tr></table>comunica@vhir.org (VHIR)Tue, 2 Sep 2014 00:00:00 GMTCAMFIC allocates the 0.7% of its budget on a project led by VHIR and PROSICS in Angola (13/08/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=176&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0176\2014_0176_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Catalan Society for Family and Community Medicine (CAMIFIC) will donate nearly 12,000 euros, which is the 0.7% of its budget, to the project “Improvement of the treatment and quality of life of patients with tuberculosis in an area of Angola with high prevalence of the disease”, led by researchers from Vall d’Hebron Institute of Research (VHIR) and the International Health Program of the Catalan Institute of Health (PROSICS). The society concluded in a statement that the project was awarded for its research dimension, its commitment to telemedicine and its orientation towards the health co-development. The study is carried out at VHIR by the groups of Infectious Diseases and Microbiology. Since 2008, researchers and clinicians from Vall d’Hebron have worked closely with the Nossa Senhora da Paz Hospital, located in the centre-east of Angola. Since then, they are maintaining a telemedicine program to share clinical cases, and conducting several studies about the resistance to tuberculosis, the epidemiology of schistosomiasis, and the relationship between malaria and child mortality. A couple of months ago, they installed in Angola the first automatic system to diagnose multidrug-resistant tuberculosis, thanks to an agreement with the Probitas Foundation. </td></tr></table>comunica@vhir.org (VHIR)Wed, 13 Aug 2014 00:00:00 GMTDr. Patricia Pozo launches 'midolordecabeza.org' to deal with headache (08/08/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=175&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0175\2014_0175_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Dr. Patricia Pozo, head of the Headache &amp; Neurological Pain at Vall d’Hebron Institute of Research (VHIR), launched 'www.midolordecabeza.org', together with renowned neurologists from the Hospital Ruber Internacional in Madrid, the Hospital Clínico Universitario in Santiago de Compostela and Hospital Clínico in Valencia. The aim of the website is to organize the information about headache, including the latest advances in research, and make it accessible and useful for both patients and doctors. The website describes the different types of headache and its symptoms, how it is diagnosed, what the treatment consists of and which are the possible complications. It also includes a glossary with all the related terminology, and the explanation of the possible causes and consequences of the different types of headache. Research is also considered in the website. There is a detailed explanation about the main fields of study: detection of new headache entities, epidemiologic and genetic studies, basic research in experimental animals, cells or tissues, and functional neuroimaging research. The group led by Dr. Pozo at VHIR involves all these research lines, and pays special attention to migraine. Through the same website, it is possible to make a donation in order to support the research of this group of scientific excellence. Finally, the new website has two sections devoted to patients: the first one is focused on contents related to daily life or the occasional moments requiring attention such as work, holidays, pregnancy and exercise; the second one is a community which includes a forum for patients and doctors, and a medical history registry that can be used to connect patients with neurologists. </td></tr></table>comunica@vhir.org (VHIR)Fri, 8 Aug 2014 00:00:00 GMTDr. Rello is reelected chair of the Critically Ill Patients group of the ESCMID (07/08/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=174&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0174\2014_0174_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Dr. Jordi Rello, head of the Clinical Research and Innovation in Pneumonia &amp; Sepsis at Vall d’Hebron Institute of Research (VHIR), was reelected chair until 2016 of the Critically Ill Patients group of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). VHIR’s researcher founded the group 3 years ago and since then they have been very active, with several educational and research activities. They are currently conducting an international multicenter study with the aim to assess new definitions of respiratory diseases in the intensive care units for the Centers for Disease Control (CDC). Vall d’Hebron participates in the study, together with the Hospital General Universitario de Alicante and more than 30 hospitals from Australia, China, Lebanon, Turkey, Greece, Croatia, Italy, Slovenia, France and Portugal. They are also leading, at Vall d’Hebron and with the participation of European, American and Australian researchers, the first guidelines of clinical practice about the use of nebulized antibiotics in patients with artificial ventilation, with the collaboration of the Cochrane. The mission of the Critically Ill Patients group is to promote knowledge of infections of critically ill and ICU-admitted patients, with focus on infections from multidrug-resistant pathogens. The group consists of 35 active members, with the representation of intensivists, infectologists, microbiologists, and specialists in nursery, pharmacology, surgery and respiratory diseases. </td></tr></table>comunica@vhir.org (VHIR)Thu, 7 Aug 2014 00:00:00 GMTA study of the Infectious Diseases group at VHIR receives the Emanuel Wolinsky Award (06/08/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=173&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0173\2014_0173_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The editors of the prestigious journal Clinical Infectious Diseases have selected a study coordinated by the Infectious Diseases group at Vall d’Hebron Institute of Research (VHIR), to receive the Emanuel Wolinsky Award for the most outstanding clinical study published in the journal during 2013. The research, entitled “Ampicillin Plus Ceftriaxone is As Effective As Ampicillin Plus Gentamicin for Treating Enterococcus faecalis Infective Endocarditis (EFIE)”, was conducted through the Spanish network in infectious pathology (REIPI), and involved 17 Spanish hospitals and a Italian one. In this observational, nonrandomized and multicenter study, researchers demonstrated that a new antimicrobial pattern, made by Ampicillin plus ceftriaxone, appears as effective as ampicillin plus gentamicin for treating patients with enterococcus faecalis infective endocarditis. The main advantage of the new therapeutic harm is that can be used with virtually no risk of renal failure and regardless of the high-level aminoglycoside resistance status of E. faecalis. The editors of the journal highlighted that “this ambitious study provides useful clinical data in a field in which information is scarce and therapeutic alternatives are limited”. They also underlined that “it adds important data to the evolving paradigm of treating enterococcal IE and opens avenues for relevant clinical trials in the future”. VHIR researchers will receive the award on October 6th, at the ceremony of the Infectious Diseases Society of American (IDSA) in Philadephia, USA. To date, any article written by Spanish researchers had obtained this award, endowed with 1,000 euros. </td></tr></table>comunica@vhir.org (VHIR)Wed, 6 Aug 2014 00:00:00 GMTFirst meeting with the UK ME/CFS Biobank to standardize protocols (04/08/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=172&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0172\2014_0172_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Chronic Fatigue Working Group, led by Dr Jose Alegre at Vall d’Hebron Institute of Research (VHIR), held the first meeting with the UK ME/CFS Biobank in order to create and standardize a biobank on Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME) at Vall d’Hebron University Hospital. Vall d’Hebron has the highest number of biological samples in Spain, from more than 1,600 CFS/ME patients collected over the last 20 years, according to the diagnostic criteria established by Fukuda et al. in 1994. The aim of the meeting was to establish the same diagnostic criteria and the same methodologies and laboratory parameters, so that VHIR researchers could collect and exchange samples with international biobanks in order to get consistent results. Dr. Alegre reported that “this initiative could revolutionize the understanding of this still poorly-understood disease and enhance development of new diagnostic biomarkers and treatments”. At this first meeting, leaders of both biobanks talked about the methodology and processing to collect human biological samples for use in research (blood, DNA, RNA, urine, cerebrospinal fluid, mononuclear cells (PBMC) and tissues such as brain and muscle). Afterwards, they shared the most appropriate methods to compare the immunological assays of fresh whole blood with frozen cells from the same patient. Finally, the meeting ended with a discussion about the ethical, social and legal issues that a biobank must accomplish. The UK ME/CFS Biobank, located at the London School of Hygiene &amp; Tropical Medicine (LSHTM), was founded in 2004 and it is the first repository of human biological samples from patients with ME/CFS in the world. </td></tr></table>comunica@vhir.org (VHIR)Mon, 4 Aug 2014 00:00:00 GMT"I was blocked when the doctors told me that they had a liver for me" (29/07/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=170&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0170\2014_0170_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> On September 21 the neighbourhood of Horta in Barcelona will host the Nick Festes d’Horta race dedicated to liver transplantation at Vall d’Hebron Institute of Research (VHIR). The organizer, María José Moscoso, shares her experience during the last 8 months after the liver transplantation and presents the latest news of the race. How did you receive the call from the hospital? Like if I was in a movie… I was blocked when the doctors told me that they had a liver for me. Although it was the long-awaited call, I was shocked. Fortunately, I didn’t have time to think about it. I took a shower, packed a few things and went to the Vall d’Hebron hospital. After some tests and screenings, I underwent surgery on October 5. Everything went very quickly. What do you remember about those days? It was a mental experience with very strange feelings.&nbsp; At the ICU I didn’t know if I had pain, but a few days later, I felt a severe back pain. Besides the pain, I felt lost, I didn’t know where my body was and the treatment to prevent rejection made me nervous, raised my pulse and caused me tremors. At the beginning I felt strange things. When did those feelings stop? When I decided to change the story, stopped fighting and started to accept my new liver instead. The most beautiful moment that I remember was when a few days after the surgery the doctor took me to the ultrasound scan room. I was crying because I knew that if something went wrong, the doctor would realize it in that test. Once in the room, the doctor touched my shoulder and explained to me, while we were watching the liver, how it worked. I felt that touch as an embrace and the good news as a miracle. I couldn’t believe that everything was ok! That was 8 months ago. How are you now? I’m fine after all that I’ve went through. I had hard moments, both emotionally and physically. The organ works perfectly and I only have a problem with the bile duct. Because of that, I have a catheter that it is a little bit uncomfortable, especially when I practice sport. Despite everything, I keep my normal life and people who know me, but didn’t know anything about my disease, don’t believe that I had a liver transplant. <span style=" font-size: 8pt; font-family: 'Verdana', 'Geneva', sans-serif; font-style: normal; font-weight: normal; color: #555555; background-color:</td></tr></table>comunica@vhir.org (VHIR)Tue, 29 Jul 2014 00:00:00 GMTVHIR coordinates the implementation of a diagnostic tool for Alpha-1 antitrypsin deficiency screening (24/07/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=168&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0168\2014_0168_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Catalan Center of AATD, associated to the Pneumology Service and the research group at Vall d’Hebron Institute of Research (VHIR), is one of the coordinators of an international study for the implementation and validation of a diagnostic in vitro tool for Alpha-1 antitrypsin Deficiency (AATD) screening. The technique, called AlphaKit QuickScreen, provides information about the presence of the most frequent deficient mutation by capillary blood obtained from the fingertip in the outpatient clinic and within 15-30 minutes. The study is also coordinated by the Marburg Hospital in Germany and also participate the Biochemistry laboratories at Vall d’Hebron. The aim of is to allow the diagnosis of this rare disease to physicians who work in chronic obstructive pulmonary disease (COPD). With the new technique, Dr. Marc Miravitlles, coordinator of the Catalan Center of AATD, is convinced that "we will help with the prevention and treatment of lung emphysema, which is the most severe complication of the disease”. AATD is an inherited disease characterized by low levels of AAT and an increased risk of developing liver disease and emphysema at an early age. Despite it is one of the most common genetic diseases, it has an important underdiagnosis:&nbsp; to the Spanish registry estimates that only 4% of the cases in Spain have already been diagnosed. The laboratory diagnosis is performed by the quantitative determination of AAT in serum and the determination of the corresponding phenotype. Scientific societies and the World Health Organization recommend to perform a determination of AAT to every patient with COPD. However, Dr. Miravitlles alerts that “factors such as the lack of knowledge about the disease or methods and diagnosis paths can contribute to not perform”. The Catalan Center of AATD launched a new website with more information about the disease and their projects. </td></tr></table>comunica@vhir.org (VHIR)Thu, 24 Jul 2014 00:00:00 GMTDr. Gámez obtains funding for two projects in the "Retos-Colaboración 2014" call (22/07/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=167&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0167\2014_0167_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Peripheral Nervous System group, led by Dr. Josep Gámez at the VHIR, obtained funding for two collaborative projects with the biotech industry, awarded by the National Program for Reseach, Development and Innovation for 2014-2016. The granted amount was of 142,805 euros and 92,563 euros each. Dr. Gámez underlines the fact that ¨VHIR received support for two projects, despite the call being highly competitive”. He also highlights “the great importance of establishing collaborations with private industry for the advancement of biomedical research and the development of new treatments”. The first project involves the VHIR, Minoryx Therapeutics, Ascil Biopharm, Reig Jofre laboratories and the University Clinic of Navarra, and its goal is to develop a drug derived from pioglitazone for the treatment of x-linked adrenoleukodystrophy (ALD), a genetic neurodegenerative disease without cure for the moment. ALD is due to the accumulation of very long chain fatty acids in plasma and tissues (in particular the brain), and symptoms include behavioural, visual and auditive disorders, epileptic fits and dementia. Thus, it is a potentially lethal and debilitating disease on the long term, due to the damage in brain and nerves. Pioglitazone, already used for treating diabetes, has been explored in ALD and other neurodegenerative diseases, but with little clinical effect. According to the consortium, this is due to its low circulating levels in the central nervous system. They propose innovative strategies to design an analog or a new formulation of the molecule that allows increasing such levels and that represents a better overall risk/benefit than the currently commercialized form used for diabetes. This will also permit the generation of considerable intellectual property concerning the new formulations and their use. The goal of the second project, that involves VHIR, SOM Biotech, and the Universitat Autònoma de Barcelona (UAB), is to develop a drug for the treatment of amyloidosis by transthyretin (ATTR), an irreversible and fatal orphan disease caused by the aberrant accumulation of the transthyretin protein (ATTR) in different organs.&nbsp; ATTR belongs to the family of amyloid diseases, characterized by protein aggregation and accumulation of insoluble deposits in tissues and organs, with often fatal consequences. They have a total incidence of 3.3 for each million persons in Spain. The project´s aim is to take to the clinical phases a drug whose activity in ATTR treatment was detected by SOM Biotech via a virtual screening technique capable of identifying new therapeutic activities of existing drugs. Studies performed by the company show that, in different experimental settings, the drug can stabilize the </td></tr></table>comunica@vhir.org (VHIR)Tue, 22 Jul 2014 00:00:00 GMT'La soledad del abecedario' tells the story of a patient with chronic fatigue (21/07/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=166&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0166\2014_0166_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> “I was the athletics runner-up in Spain when I was 18 and now I can hardly find the words to describe the pain that people with chronic fatigue feel”. With this message, Fernando Novalbos presents ‘La soledad del abecedario’, a novel about the story of a patient with chronic fatigue. The 30% of the profits will be donated to the research in this syndrome, led at Vall d’Hebron Institute of Research (VHIR) by Dr. José Alegre. The main character is diagnosed by chance in a moment of his life in which “he has to deal with things related to love”, the author reported. It is a positive story in which the disease is not an impediment to achieve his challenges. Dr. Alegre recommends this book to all the society and especially to the patient’s families because it explains how this disease not only produces fatigue, but also induces a severe cognitive impairment. In this sense, he acknowledges the merit of the author because “the chronic fatigue syndrome presents serious reading and learning difficulties”. The book, edited by Ara Llibres, can be ordered from La Casa del Libro and other online sales platforms. </td></tr></table>comunica@vhir.org (VHIR)Mon, 21 Jul 2014 00:00:00 GMTThree undergraduate students share their experience at VHIR (18/07/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=165&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0165\2014_0165_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Carla Rossell, student of the first year of the Human Biology Degree at Universitat Pompeu Fabra and winner of the Catalan awards of excellence in high school: “I’ve seen at first hand the routine of a scientist and I love it! I chose the Vall d’Hebron because it is very renowned, very big, with many research areas and a lot of publications. I didn’t know which group to choose for the one-week traineeship, because I liked all of them, so I asked for advice to Núria Prim (lab coordinator). She introduced me to the Cell Signaling and Apoptosis group. I am very happy. I've done a lot of things! Honestly, I didn’t expect that I was going to do such an amount of techniques... Every member of the group told me about their projects and I participated in some of their tasks. It was very useful because I practiced different things that I learned on my first year in college, but I hadn’t practiced yet. All things considered, I would definitely repeat the experience! Daniel Villodres, student of the first year at the IES Banús high school in Cerdanyola del Vallès and participant of the 6th edition of the ‘Joves i Ciència’ programme of the Fundació Catalunya la Pedrera (watch the video): “I participated in the 6th edition of the ‘Joves i Ciència’ programme. They offered me a two-week traineeship at VHIR in order to learn the daily routine in a lab. To sum up, it’s been a great experience. I’ve learned new techniques, how do they work, and who is behind the outstanding research carried out at Vall d’Hebron… Great people! I also learned the aim of the research and the differences between clinicians and researchers. The work environment is great and I have realized that without clinicians, researchers wouldn’t have samples. And samples are essential to investigate proteins and find the cure of cancer, which is the main mission of the endometrial cancer research line conducted at the Research Unit in Biomedicine and Translational Oncology”. <span style=" font-size: 8pt; font-family: 'Verdana', 'Geneva', sans-serif; font-style: normal; font-weight: bold; color: #555555; background-color: transparent; text-decorati</td></tr></table>comunica@vhir.org (VHIR)Fri, 18 Jul 2014 00:00:00 GMTMeeting on nanomedicine, personalized medicine and biomarkers (14/07/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=160&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0160\2014_0160_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Nanomedicine is no longer a commitment to the future, but a reality more and more extended. Among its applications, researchers use it to obtain early diagnosis of different diseases, more efficient drugs and alternative therapies to the most aggressive treatments. Expoquimia, the reference event in the chemical industry, will have a space dedicated exclusively to nanomedicine, as in the last successful edition. The Vall d’Hebron Institute of Research (VHIR), which comprises and area dedicated to nanomedicine, is the organizer of this debate about the present and the future of nanomedicine, led by outstanding scientists and pharmacists. The meeting will take place on October 2 at Expoquimia and will deal with the current state of nanomedicine, personalized medicine and biomarkers. Participants will also focus in the perspectives of translation of the results to the society. Chaired by VHIR’s director, Dr. Joan Comella, three lecturers will participate in the meeting: Dr. Josep Tabernero, head of the Oncology Service at the Vall d’Hebron University Hospital, Dr. Víctor Franco, ICREA professor and researcher of the Catalan Institute of Nanoscience and Nanotechnology (ICN2), and Dr. Artur Palet, director of Business Development in Spain of Roche Diagnostics. <p style=" text-align: le</td></tr></table>comunica@vhir.org (VHIR)Mon, 14 Jul 2014 00:00:00 GMTVall d'Hebron improves burn scars by injecting adult stem cells from the patients (14/07/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=162&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0162\2014_0162_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Plastic Surgery and Burns Service at Vall d’Hebron University Hospital has successfully improved the treatment of burn scars, especially the ones that affect a considerable amount of skin surface, with the application of regenerative techniques using adult stem cells derived from the patient's adipose tissue. By now, the technique has been used in 2 patients, even though it can be applied in a wide number of patients, especially when they have consequences in large areas on the body. The patient’s tissue is obtained performing small precise incisions, from which the adipose tissue is extracted to isolate adult stem cells and the mesenchymal fraction. Once prepared, they are injected again into the scars and in the new tissue using tools of extremely small diameter that allow the introduction of a very small number of cells in each treated area. Thus, the mesenchymal stem cells create a microenvironment in the tissue that stimulates the growth of new vessels, secrete growth factors and promote new molecular structures that regulate the collagen deposition (part of the scar) and increase the elastic elements, which create, in long term, a new physical structure more alike to normal tissue. The aim of this innovative treatment is to improve the elasticity, flexibility and vitality of the scar tissue and diminish the unsightly consequences. The cells and implanted tissue can settle in the tissue and create a new structure inside the scars, which allows a better architecture of the new dermis, increasing its functional ability. This leads to a significant improvement in the quality of life of the patients, thanks to an increase in tissue flexibility, better hydration and improvement in the outlines of the scars. The benefits of this kind of therapy, which can be transferred to any other atrophy on soft tissue, are evident in a few months' time, as the stem cells regenerate and optimize the quality of the tissue after a reasonable time from the implant. Dr. Joan Pere Barret, head of the Plastic Surgery and Burns claims that “this is an innovative technique because we give biological treatment to the burns. Through the injection of cells and tissue we alter the biological structure of the tissue, performing a regenerative treatment that contrasts with the usual surgical techniques, which alter its form and function but not its quality, as we create new scars. With the new technique, we minimize the damage of the same surgery and provide benefits”. This technique goes in line with the new repair and plastic surgery, which aims at performing highly individualized and minimally invasive specialized treatments. In this regard, 5 years ago the Plastic Surgery and Burns service, through its team at Vall d’Hebron Institute of Research (VHIR), started conducting clinical research on the application of new techniques of regenerative surgery. An example of this is the use of stem cells in the reconstruction of serious facial disfigurement in children with Parry-Romberg syndrome, a pathology that produces severe malformations in the facial features. Thanks to a surgery performed at the Vall d’Hebron Hospital, the appearance and clinical evolution of these children is greatly improved. </td></tr></table>comunica@vhir.org (VHIR)Mon, 14 Jul 2014 00:00:00 GMTEls Amics de les Arts gave a benefit concert for research in child cancer at VHIR (12/07/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=157&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0157\2014_0157_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Catalan pop band Els Amics de les Arts offered, on Friday 11, a benefit concert at the Bullring located in Olot, to present their last album ‘Només d’entrar hi ha sempre el dinosaure’. The A. Bosch foundation organized this performance with the aim to contribute to research in children’s cancer at the Vall d’Hebron Institute of Research (VHIR), led by Dr. Josep Sánchez de Toledo. All proceeds of the concert go to support the studies of the Translational Research in Child Cancer group. Specifically, the A. Bosch foundation is already collaborating in three projects to improve the therapies for child cancer, investigate the myelomeningocele (spina bifida) and the lupus erythematosus. The foundation was created in 2004 by Noel Alimentaria, with the aim to promote research and clinical solutions to childhood diseases.  The Olot city council, Natrus, La Fageda, Sant Aniol, Moritz and B-Crek sponsor the concert and the party that started two hours before with the performance of CyBee. </td></tr></table>comunica@vhir.org (VHIR)Sat, 12 Jul 2014 00:00:00 GMTA research team in VHIR reveals unexpected functions for a ribosomal protein in embryonic cells (10/07/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=156&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0156\2014_0156_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> A study published in PlosOne by the Molecular Pathology and Oncology group of the VHIR, directed by Dr. Matilde Lleonart,&nbsp; has revealed a crucial —and unexpected— role of a ribosomal protein, called P1, in the embryonic development of the nervous system. The project started 8 years ago, when the group led by Dr. Lleonart was seeking genes that could induce proliferation. They identified the P1 protein whose expression turned out to be increased in human tumors. In this study, performed in collaboration with researchers from the Leibniz Institute for Age Research, Jena, Germany, the authors wanted to understand the relevance of P1 in vivo. In other words, what happens when the protein is absent? They found that mice completely deficient for the protein (because both P1 alleles were inactivated) died before birth, while mice with one inactivated allele survived after birth but presented many defects such as reduced size, brain atrophty, an arrest in cell proliferation and an increase in cell death. The ribosome is a complex cellular factory where all new proteins are formed. Thus, defects in ribosomal proteins should lead to defects in protein synthesis. However, explains Dr. Lleonart, “the most surprising thing is that we did not find a defect in protein synthesis” Rather, P1 deficiency led to an increase in stress proteins that in turn results from an accumulation of mis-folded proteins. “This suggests that the protein has an extra-ribosomal function associated to protein folding” says Dr. Lleonart. Another unexpected result, according to the investigator, is that P1 disturbance particularly affects proliferating cells, very likely as a strategy to detect cellular stress and ensure their integrity as stem cells. “The role of the protein may depend on the tissue” concludes Dr. Lleonart, “since its deficiency </td></tr></table>comunica@vhir.org (VHIR)Thu, 10 Jul 2014 00:00:00 GMT"ISHR Best Poster Award" for a study by the Cardiovascular Diseases group (08/07/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=155&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0155\2014_0155_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Celia Fernandez-Sanz, a pre-doctoral student of Dr. Marisol Ruiz-Meana in the research group on Cardiovascular Diseases of Vall d’hebron Institute of Research (VHIR) has won the ISHR Best Poster Award in the recently concluded joint meeting of the International Society for Heart Research (ISHR) and the Council of Basic Cardiovascular Science of the European Society of Cardiology (Barcelona 3-6 of July 2014). The awarded work, conducted in collaboration with CNIC under the direction of Dr. Ruiz-Meana, describes a new mechanism of altered function in cardiac cells in advanced age, consisting in an alteration of the communication between two important organelles within those cells, the mitochondria and the sarcoplasmic reticulum, and used sophysticated analyses of cell physiology with in vivo confocal microscopy and advanced proteomic methods. In fact, the research groups in cardiovascular diseases have been the local hosts in this congress, the 32nd meeting of the European Section of the ISHR - a success well above the expected assistance: more than 250 participants on the 3rd of July and more than 700 total considering the joint meeting between ISHR and FCVB (Frontiers in Cardiovacular Biology), where the prized poster was also exposed. The goal of this international society is to promote the exchange of ideas between scientists and clinicians in the field of cardiovascular biology and medicine. Besides the award, it should be noted that Drs. Ruiz-Meana and Dr. García-Dorado, coordinator of the cardiovascular disease area, chaired some of the congress sessions, and Dr. Ruiz-Meana is member of the European Council of the ISHR. </td></tr></table>comunica@vhir.org (VHIR)Tue, 8 Jul 2014 00:00:00 GMTNew species detected in intestinal microbiota that make the difference between healthy and unhealthy individuals (06/07/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=154&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0154\2014_0154_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> A team of researchers from the Vall d’Hebron Institute of Research (VHIR), headed by Dr. Francisco Guarner, are the only Spanish participants in two studies that extend the MetaHIT Project. Both studies, published this Sunday July 6 in the Nature Biotechnology journal, represent one more step towards the knowledge of the intestinal microbiome. The first article provides an integrated catalog of gut microbial genes, which has increased from 3 to 10 million.&nbsp; Such a catalogue will allow scientists to determine the genetic and functional repertoire of a given gut microbiome and to understand how it is affected by geographical, temporal and physiological factors. Interestingly, the study reveals contry-specific gut-microbial signatures, as well as the presence of genes associated to antibiotic resistance. The second article explains how, thanks to a new approach in the analysis of complex metagenomic samples, more than 500 species have been identified in the human microbiome that were completely unknown until now. There is another landmark to add: not all the studied samples display such a high amount of unknown species. The intestinal flora of some individuals shows a smaller amount of unknown species and, in further analysis, it has been found to correspond to samples of patients diagnosed with Crohn’s disease. “This brings up new data which we have to explore in detail”, explains Dr. Francisco Guarner, “these species, unknown until now, will possibly make the difference between healthy and unhealthy people”. These data are highly relevant because they open the door to new strategies aimed at recovering all these species through nutritional interventions: administering probiotics or fibers and other prebiotics that help the selective growth of some species. These unknown bacteria are most certainly the “good bacteria”, as they are not the typical strains that produce an infection and this is the reason why they weren’t isolated never before. “In these cases the stool transplant is not useful because they are most likely labile species, strictly anaerobic and dependent of the environment and,most certainly wouldn’t survive outside the colon during the transplantation. The risk is that the transplant would favour the proliferation of non desirable species”, continues Guarner. </td></tr></table>comunica@vhir.org (VHIR)Sun, 6 Jul 2014 00:00:00 GMTDr. Ferran Morell captains the Catalan team in the World Medical Football Championship (04/07/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=153&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0153\2014_0153_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The 20 doctors that take part in the Galens Catalonia team are ready to demonstrate their level and retake the title of the World Medical Football&nbsp; Championship, won five times, the last one in 2011. This year’s edition is special, because it takes place in Natal, Brasil, at the same time of the FIFA World Cup, and because it is the 20th edition of this championship created by Dr. Ferran Morell, head of the Pneumology Research group at Vall d’Hebron Institute of Research (VHIR). The Galens Catalonia will participate in the tournament from the 6th to the 12th of July coinciding with the last week of competition of the World Cup. The team was also founded by Dr. Morell in 1974 and they quickly participated in first level international competitions, until the creation of the World Medical Football Championship in 1995. Barcelona hosted for 10 years this Cup –also called Dr. Ferran Morell’s Cup– and since then, the competition has been hosted in countries such as Australia, Lithuania, South Korea, Sweden, Great Britain and Austria. In the last edition, that took place in Hongria, the German selection triumphed among the 15 participant countries. The Spanish-Catalan team comprises 10 doctors from the Vall d’Hebron University Hospital, and clinicians from the Hospital del Mar, Hospital Esperit Sant, Hospital Clínic, Hospital de la Santa Creu i Sant Pau, Hospital de Terrassa, Hospital Meritxell from Andorra, Hospital Son Llàtzer and Clinica Miramar from Mallorca, and the Hospital Insular from Las Palmas de Gran Canaria. For the captain, Dr. Morell, “all these years of the championship have represented a major benefit for the relationship between doctors at the hospital and to create many friendships here and abroad”. Besides the physical exercise, the football players always celebrate a symposium where they explain what they do with the T-shirt that they wear the rest of the year, the doctor’s coat. </td></tr></table>comunica@vhir.org (VHIR)Fri, 4 Jul 2014 00:00:00 GMTVHIR and the Probitas Foundation install in Angola the first automatic system to diagnose multidrug-resistant tuberculosis (03/07/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=152&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0152\2014_0152_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Vall d’Hebron Institute of Research (VHIR) and the Probitas Foundation implemented in the Nossa Senhora da Paz Hospital in Cubal, in the east central part of Angola, a fast and automatic genotypic test that will, for the first time in the country, diagnose tuberculosis and determine whether is multidrug-resistant. The Xpert MTB/RIF (GenXpert Cepheid) equipment can identify the disease with sputum samples in 1 hour 45 minutes. With the incorporation of this technology, the diagnostic time of multidrug-resistant tuberculosis will be remarkably reduced: until now the diagnostic was done by clinical suspicion or after microbiological failure in the 5th month of the treatment. Dr. Israel Molina, director of the International Health Programme of the Catalan Institute of Health (PROSICS) and researcher of the Infectious Diseases group at VHIR, is convinced that “the patient’s survival rate will improve because the treatment will be administered sooner, and for that reason, the time of contagiousness will be also reduced”. The researchers of the Microbiology group at VHIR, led by Dr. Tomàs Pumarola, will receive over 500 samples from the hospital in Cubal in order to undertake a pioneer study on the prevalence of multidrug-resistant tuberculosis in the area. They will analyze the drug sensitivity through conventional means, following the recommended flow chart. The epidemiological knowledge of multidrug-resistant tuberculosis will help to establish therapeutic guidelines with the aim to reduce the morbidity and mortality rate of the disease within the area. The World Health Organization have recommended since 2010 the GenXpert system to diagnose tuberculosis; a disease that in Angola affects 300 out of 100.000 inhabitants and has a cure rate of the 70%, one of the worst in Africa. With the arrival of the technology to the hospital, the equipment and the knowledge of the professionals from Vall d’Hebron and PROSICS will be transferred and kept by the local partner that will integrate the system in the national public health network. The project is a part of the collaboration with the national program against tuberculosis. The Angolan government will provide the second-line drugs which are needed for the treatment of the patients diagnosed.&nbsp; </td></tr></table>comunica@vhir.org (VHIR)Thu, 3 Jul 2014 00:00:00 GMTNew games for children with pediatric cancer (01/07/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=150&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0150\2014_0150_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Bernat and his friends with pediatric cancer treated at the Pediatric Oncology Service at Vall d’Hebron University Hospital are playing this week with the new games donated by Gargamel Joguines, a toy shop located at Vic. The owners of the store are relatives of a researcher from the Translational Research Unit in Child Cancer, led by Dr. Josep Sánchez de Toledo. The donation is not punctual; they will renovate the games according to the interaction of the children. With this action, the manager of the store, Miquel Molist, aims to “participate in an integrative and transversal long-term project with different children”. All toys donated are pedagogic and written in different languages. Gargamel Joguines promotes the games as a relational and learning method. Since 2012, they have organized activities with games in neighborhoods, entities, associations and schools. </td></tr></table>comunica@vhir.org (VHIR)Tue, 1 Jul 2014 00:00:00 GMTDiscover what researchers see and create (01/07/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=109&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0109\2014_0109_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> “Research in the forefront: discover what researchers see and create”; this is the title of the exhibition hosted at Els Lluïsos de Gràcia and&nbsp; the Pavelló Docent that the 4th of July comes to the Maternal-pediatrics at the Vall d'Hebron University Hospital until August 31, with the best pictures taken from the last three editions of the scientific photo competition of the Vall d’Hebron Institute of Research (VHIR). The exhibition features 18 stunning pictures, most of them obtained by the state-of-the-art microscopes that reveal impressive hidden parts of our body, such as the peculiar shape of the intestinal surface and the cells which allow heart contractions. This exhibition is one of the events organized by the VHIR for its 20th anniversary. Don’t miss it, admission is free! </td></tr></table>comunica@vhir.org (VHIR)Tue, 1 Jul 2014 00:00:00 GMTIdentified a new mechanism that could be involved in the etiology of ADHD (26/06/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=147&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0147\2014_0147_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> A study led at Vall d’Hebron Institute of Research (VHIR) and the Centre for Genomic Regulation (CRG) has concluded that the ubiquitination machinery could be a new mechanism involved in the etiology of the Attention Deficit Hyperactivity Disorder (ADHD). Dr. Marta Ribasés, researcher of the Psychiatry, Mental Health and Addictions research group at VHIR, presented at the XV Symposium of the Marató de TV3 Foundation the results of this study funded with 350,000 euros in the 2008 edition. For this study, researchers carried out the first case-control genome-wide association study (GWAS) and a copy number variation analysis in adults with ADH and controls. The results also revealed that structural variants may also contribute to adult ADHD, which is the genetic burden of the disease and that there is a genetic relationship between the five most common psychiatric disorders. These results have been published in papers such as Nature Genetics and Journal of Psychiatric Research. Thanks to this research, Dr. Ribasés assures that “new therapeutic drugs could be designed in the future, as well as individualized and intensive programmes”. The 2008 edition of La Marató was dedicated to severe mental health disorders such as depression, schizophrenia, anxiety and bipolar disorder. A total of 6.9 million euros funded 25 research projects that today have been presented at the Institut d’Estudis Catalans building. </td></tr></table>comunica@vhir.org (VHIR)Thu, 26 Jun 2014 00:00:00 GMTDr. Aasen reveals the internal translation of a protein associated to cancer and other pathological conditions (25/06/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=146&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0146\2014_0146_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Dr. Trond Aasen, principal investigator of the Molecular Pathology group at Vall d’Hebron Institute of Research (VHIR), has identified how is regulated connexin 43, which is the most widely expressed gap junction protein, and how several protein isoforms can be translated from a single mRNA transcript. The study has been recently published in Cell Communication and Signaling. Direct communication between adjacent cells is mediated through gap junction channels, a process critical for embryonic development and tissue homeostasis. Connexin 43 has been implicated in a number of important diseases including cancer, cardiac disease and neuronal disorders and its mutations also causes oculodentodigital dysplasia, a multifaceted rare syndromic disease. Connexin 43 is generated from a single mRNA transcript and normally resides in the cell membrane but protein expression levels and subcellular localization are frequently altered in many pathological conditions. The study demonstrates that internal translation of the gene transcript occurs, generating smaller protein isoforms that do not target to the cell membrane. “Surprisingly, we have shown that translation is cap-dependent and not due to a classical IRES-dependent mechanism”, reports Dr. Aasen. He has also demonstrated that the kinases Mnk1/2, in addition to the mTOR kinase, can regulate the ratio between full-lenght protein and the smaller isoforms. The Molecular Pathology group, led by Dr. Santiago Ramon i Cajal, is now correlating the activation of these pathways with the subcellular reorganization of connexin 43 that frequently occurs during cancer development. The lab is also continuing to elucidate how internal translation is mediated, which may answer key questions on how increased protein divesity is generated from a single RNA transcript. </td></tr></table>comunica@vhir.org (VHIR)Wed, 25 Jun 2014 00:00:00 GMTVHIR: twenty years of research committed to people's health (20/06/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=144&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0144\2014_0144_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The blog of the Institut Català de la Salut published on Friday a report about VHIR’s history, coinciding with the 20th anniversary: “Vall d’Hebron Institute of Research (VHIR) celebrates this year a special anniversary: twenty years ago was founded the Fundació per la Recerca i la Docència Vall d’Hebron –since 2011 called VHIR–, which has become one of the most important biomedical research institutions of our country. However, many years before its foundation, doctors from Vall d’Hebron University Hospital were already investigating. It is the case of the Department of Internal Medicine that in 1970 began to investigate despite the few resources available. Since that year, many initiatives started to rise inside the hospital and eventually converged in a single project. In that time, the main research activity was concentrated in the laboratory of Dr. Simó Schwartz’s father, who created the Center for Biomedical Research in Biochemistry and Molecular Biology (CIBBIM) in 1995. Dr. Schwartz also headed the Santiago Grisolía Metabolic Research Unit, founded in 1992. Another laboratory that played an important role in the foundation of the Institute was the Unit in Experimental Cardiology, located at the manager’s garage of the Ciutat Sanitària. The creation of the foundation was very welcome among the professionals of the hospital. Before 1994, many projects received regular funding from the Fondo de Investigaciones Sanitarias (FIS), the Spanish National Plan and the European Comission. When the Foundation was born, the groups quickly transferred their calls and projects to the new entity, which demonstrated their confidence in the amazing project that had just started". </td></tr></table>comunica@vhir.org (VHIR)Fri, 20 Jun 2014 00:00:00 GMT Study of the Catalan government concludes that VHIR generates the double of its budget (19/06/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=142&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0142\2014_0142_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> For each euro that the Vall d’Hebron Institute of Research (VHIR) spent in 2012, generated 2, according to a monographic study of the Chamber of Comerce and the Central de Resultats about the two biggest research institutes of health in Catalonia. The Catalan government presented this study and another one that concludes that for each euro that they invested, the Institute raised 19. The monographic compared the results of the VHIR, excluding the Vall d’Hebron Institute of Oncology (VHIO), with the&nbsp; August Pi i Sunyer Biomedical Research Institute (IDIBAPS) and the Clinic Foundation for Biomedical Research, both associated to the Hospital Clínic in Barcelona. The study highlighted that both centers generated an economic impact equivalent to the double of their budget in 2012. Specifically, VHIR generated in the short term 68.1 million euros of economic activity, from the 32.2 millions of its budget. On the other side, the centers of the Hospital Clínic received from the Catalan government 5.6 million euros, whereas VHIR, 1.5 million euros. Nonetheless, both centers returned to the public administration the 80% and the 50% respectively of the funds obtained through public calls. Regarding the study of the 19 centers and institutes of biomedical research in Catalonia, the first conclusion is that for each euro that the Catalan government invested in 2012 in these centers, they managed to raise 3 additional euros. In the case of the VHIR is higher because from the 1.5 million euros that the Generalitat invested, they raised 28,5 million euros through competitive calls and other resources, which represents 19 euros raised for each euro granted by the Catalan government. The study also remarked the leadership of Vall d’Hebron in clinical trials: in 2012 there were in Catalonia 2,853 active clinical trials, from which one third where conducted at VHIR, with a great participation of the VHIO in the oncology treatments. Thanks to the resources obtained from the clinical trials and the agreements with the industry, VHIR obtained 18 million euros, which is much more than the rest of the Catalan research institutes of health. <span style=" font-size: 8pt; font-family: 'Verdana', 'Geneva', sans-serif; font-style: normal; font-weight: normal; color: #555555; </td></tr></table>comunica@vhir.org (VHIR)Thu, 19 Jun 2014 00:00:00 GMTUsing game mechanics to achieve healthier lifestyles (18/06/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=141&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0141\2014_0141_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The PRECIOUS project (PREventive Care Infrastructure based On Ubiquitous Sensing) aims to solve the challenge of motivating individuals to adopt healthier lifestyles using a combination of motivational interviewing and gamification principles, and taking advantage of the advances in technology. Dr. Pilar Lusilla, researcher from the Psychiatry, mental health and addictions at Vall d’Hebron Institute of Research (VHIR), is part of the project and has spoken about it this week at the International Conference on Motivational Interviewing (ICMI). PRECIOUS project aims to develop a preventive care system to promote healthy lifestyles, which is comprised of three components. First of all, transparent sensors for monitoring user context and health indicators (food intake, sleep and activity), that deliver ambient data about current user behavior. Secondly, users are represented by individual virtual models, which infer health risks and suggest behavioral changes. Finally, state-of-the-art motivational techniques originating from gamification and motivational interviews to trigger a set of feedback tools to change the user habits toward more healthy behavior. The main challenge of the project is motivating people to make lifestyle changes; this is the reason why the design is shaped around the concept of gamification, an approach that has been shown to be successful in various contexts, placing the individual at the centre of the action. The initial game design has been completed and programming of the first version is underway; pilot tests have started on May and the first laboratory experiments will take place this June. PRECIOUS is a european project, with the final objective of improving the health of the users and delivering cost savings in the public health sector. </td></tr></table>comunica@vhir.org (VHIR)Wed, 18 Jun 2014 00:00:00 GMTVHIR signs a collaboration agreement with the association of patients with Dent's disease (16/06/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=137&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0137\2014_0137_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Vall d’Hebron Institute of Research (VHIR) has signed a collaboration agreement with the association of patients with Dent’s disease, chaired by Eva Giménez, mother of a 4 year-old child with this rare disease of the kidney. The agreement will direct through the VHIR’s fundraising website 'Yo Investigo' all the donations addressed to research projects, studies and clinical trials at VHIR. Another goal is to spread the fundraising activities of the association and to improve the comprehension and knowledge of this disease. Dent’s disease is a rare X-linked recessive inherited condition that exclusively affects the kidney. It causes the loss of essential proteins for the organism and the expulsion through the urine of calcium, phosphorus, magnesium and glucose. There is not any treatment available to cure the disease and the future of these patients is uncertain. Nacho is a champion and his parents are true fighters. During Eva’s pregnancy, doctors from Vall d’Hebron found neurological problems in her fetus and she suffered several complications (iron deficiency, Toxoplasmosis infection and excessive amniotic fluid). Nacho was born in the week 35, with respiratory problems and a small hemorrhagic stroke. After several visits to the hospital, he was eventually diagnosed with Dent’s disease at the age of 18 months. Since then his parents have raised more than 100.000 euros organizing all kind of activities: collecting plastic bottle caps, organizing concerts, benefit events and even participating in the Titan Desert! Now with this agreement that they have signed together with Nacho’s doctor and head of the Nephrology Service, Dr. Gema Ariceta, they look forward to advance in the research of this disease that in Spain affects 38 people. </td></tr></table>comunica@vhir.org (VHIR)Mon, 16 Jun 2014 00:00:00 GMTThe 4th Eurocondor Annual Meeting reviews the clinical trial started in 2013 (13/06/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=135&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0135\2014_0135_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Military Hospital in Padova hosted a few weeks ago the 4th General Assembly of the Partners of the EUROCONDOR EU-funded research project, coordinated by Vall d'Hebron Research Institute (VHIR), headed by Dr. Rafael Simó, leader of the Diabetes and Metabolism group. This EUROCONDOR project aims to improve the lives of people with diabetes by developing a new treatment of diabetic retinopathy, a neurodegenerative disease of the eye. The therapeutic strategy of the EUROCONDOR project is based on neuroprotection to prevent or arrest retinal neurodegeneration in early stages of the disease. It is a prospective and randomized study in 450 type 2 diabetic patients of two neuroprotectors therapeutic agents (somatostatin and brimonidine), administered topically through eye drops. During this meeting, in which participated 37 researchers, there has been a review of the basic research that supports this clinical trial that started in February 2013 and a depth debate about the whole clinical protocol and the way of implementing it in all the participant countries. Much emphasis has been done in the safety topics, possible adverse effects, therapeutic fulfillment, and analysis of efficiency and dissemination of the results. </td></tr></table>comunica@vhir.org (VHIR)Fri, 13 Jun 2014 00:00:00 GMTDr. Albert Pahissa's retirement (13/06/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=136&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0136\2014_0136_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> More than one hundred clinicians, researchers, colleagues and friends attended the homage to Dr. Albert Pahissa, head of the Infectious Diseases Service and the group with the same name at Vall d’Hebron Institute of Research (VHIR), because of his retirement. “He is a great professional in all aspects: he is an excellent doctor, professor, researcher and manager”, pronounced at the beginning of the session Dr. Joan Comella, VHIR’s director. Dr. Jaume Roigé, director of Patient Care at the hospital, and Dr. Benito Almirante, who has worked with Dr. Pahissa since the beginning and now is the new head of the Infectious Diseases Service and the research group, also agreed with Dr. Comella’s statement. Dr. Pahissa graduated in Medicine in 1972 at the Universitat de Barcelona (UB) and got his PhD in 1979. He started his career at Vall d’Hebron in 1978 and ten years later he was promoted Head of Section and professor of Medicine at the Universitat Autònoma de Barcelona (UAB). In 1990 he created the first Laboratory of Experimental Research applied to Infectious Diseases. Eight years later he was promoted head of the first Infectious Diseases Service at Vall d’Hebron. Since then, thanks to his leadership skills he has encouraged distant research lines as well as projects of International Health that are not only conducted at VHIR, but also in Drassanes (Barcelona), Angola and many other regions around the world. </td></tr></table>comunica@vhir.org (VHIR)Fri, 13 Jun 2014 00:00:00 GMTVHIR researchers receive a grant to investigate about DMD (12/06/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=134&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0134\2014_0134_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Duchenne Parent Project Association has awarded 1 of the 3 grants for research projects about Becker and Duchenne Muscular Distrophy (DMD) to a team participated by Vall d’Hebron Institut de Recerca (VHIR) researchers, for the project “Study of the efficiency of drugs capable of restoring the dystrophin expression in myoblasts of patients suffering from DMD with nonsense mutations, analysis of the causes that condition the variability in the response and evaluation of strategies to increase this efficiency in human myoblasts and in the mdx mouse”. The project lasts 2 years and the aid amount is 25,000 euros for the first year and the same for the second, after evaluating the results from the first year. From the VHIR, the team counts on the Drs. Francina Munell (Pediatric Neurology Unit), Jordi Barquinero (Advanced Therapy Unit) and María José Pérez (Pediatric Neuromuscular Unit), and also the project will be developed together with the Hospital Universitari Vall d’Hebron (HUVH) and the IQS’ Grup d’Enginyeria de Materials (GEMAT). The project focuses in the variability of the response of the new therapies destined to reestablish the dystrophin expression in patients suffering from DMD, specifically the one focused on correcting the nonsense mutations with PCT124 (Ataluren). The aim is to understand why this segment of patients responds less to these treatments and to design new strategies destined to solve these problems. Describing the project, the researchers point that “the best way to approach it is through the collaboration of centers that have experience in neuromuscular diseases in a clinical and translational level with centers that have experience in disciplines that allow to address new mecanisms and strategies”. The DMD is considered a rare disease, diagnosed during childhood, that limits significantly the living years of the affected. It affects 1 of every 3,500 children in the world, with nearly 20,000 new cases every year. It is a progressive disorder of the muscle that causes the loss of its function, which translates in a final loss of independence for the affected and serious medical problems due to the muscle weakness. </td></tr></table>comunica@vhir.org (VHIR)Thu, 12 Jun 2014 00:00:00 GMTPractical sessions from the Master in Science and Welfare of Laboratory Animals will be taught in VHIR's experimental operating rooms (10/06/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=132&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0132\2014_0132_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Several practical sessions of the module “Reduction and Refinement of the Design and Experimental Method”, from the Master of Science and Welfare of Laboratory Animals will be taught in the experimental operating rooms of the Animal Experimentation Service (SEA) from the Vall d’Hebron Institute of Research (VHIR). Veterinarians Marielle Esteves and Carla Fonseca will coordinate this collaboration and will give some lectures about image techniques in experimental animals, as well as practical sessions about ecoguided vascular access. Other professionals will participate on the sessions, Drs. Joan Sánchez de Toledo, César G. García Fontecha, Anna Server Salvà and Iván Villaverde Castillo, from the Vall d’Hebron Institute of Research (VHIR). The practical sessions will be taken in simulators and in big animals (pigs and sheep), with the objectives of showing the students some techniques of ecoguided vascular access, and start their training. The purpose of these kinds of techniques is to perfect (“refine”) the experimental handling of laboratory animals, which affects directly in animal welfare and the quality of the studies. The SEA includes a Big Animal Area and 3 operation rooms in its facilities, one for rabbits and two for pigs and sheep. They are provided with all the basic and specific equipment for a great variety of experimental procedures: inhalatory anesthesia equipment, monitoring, laparoscopy and endoscopy tower, fibroendoscopy and scopy arch or ultrasound scanner. The researchers and doctors of VHIR use the facilities to develop projects of translational research in the surgical field, and for training in general and specific techniques, highly sophisticated, such as endoscopic surgery or interventionist radiology. This specialization master is the only one in Spain where you can obtain the qualification of animal welfare consultant, required for animal facilities responsible, and also counts on the accreditation of the European Federation of Associations for the Laboratory Animal Sciences (FELASA). There are only two master degrees in Europe with this accreditation, being a great appeal for professionals in this field, also in an international level. Besides this master’s degree, the VHIR also teaches the module of Molecular Pathology from the Official Master's Degree in Biochemistry, Molecular Biology and Biomedicine from UAB, and next academic year (2014-2015) will teach the VIHR’s </td></tr></table>comunica@vhir.org (VHIR)Tue, 10 Jun 2014 00:00:00 GMTThe new statement on the use of the term 'probiotic' includes beneficial bacteria (10/06/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=133&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0133\2014_0133_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Nature Reviews Gastroenterology &amp; Hepatology published today the new statement on the scope and appropriate use of the term probiotic, approved by the group of experts convened by the International Scientific Association of Probiotics and Prebiotics. Dr. Francisco Guarner, researcher from the Physiology and Pathophysiology of the Digestive Tract group at Vall d’Hebron Institute of Research (VHIR), participated in this new consensus that define probiotics as bacteria or microorganisms with their functions well characterized&nbsp; that can be applied into medicine for their beneficial impacts on health. The previous consensus on probiotics was endorsed 12 years ago by experts convened by the Food and Agriculture Organization of the United Nations (FAO) and the World Health Organization (WHO). They stated that “probiotics are live microorganisms that are thought to benefit health if administered properly”. Since then, Dr. Guarner explains that “science has advanced in the field of probiotics”, especially in the field of food, “but with little impact in clinical medicine because of the fact that most of the products developed have been food or nutritional supplements”. In November 2013, the International Scientific Association of Probiotics and Prebiotics brought together this new group of experts from different countries, in order to bring up to date the acquired knowledge in this area and propose a new consensus. The new document is based on the progress in the knowledge of the composition and biological characteristics of human microbiota. These findings have revealed the beneficial functions of number of bacteria that are not from the diet field, but may be useful in clinic medicine. For Dr. Guarner “there are reliable hopes that the use of bacteria could be useful in certain metabolic or immune system conditions”.&nbsp; </td></tr></table>comunica@vhir.org (VHIR)Tue, 10 Jun 2014 00:00:00 GMTDr. Ferran Morell is awarded ex aequo with the ICS Research Career Prize (06/06/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=131&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0131\2014_0131_IMATGE.JPG" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Dr. Ferran Morell, head of the Pneumology group at the Vall d’Hebron Institute of Research (VHIR), has been awarded with the Research Career Prize of the Catalan Institute of Health (ICS) in the hospital category, together with Dr. Antoni Dávalos, researcher of the Health Sciences Research Institute of the Germans Trias i Pujol Foundation (IGTP). Dr. Ferran Morell is a clinician specialized in Pneumology, PhD in Medicine and Surgery and head of the Pneumology Service at the Vall d’Hebron University Hospital, where he started the first and the only programme available in lung transplantation in Catalonia. In the academic field, he is professor of the Medicine Department of the Universitat Autònoma de Barcelona (UAB). Regarding research, he has driven several initiatives to improve the study of respiratory diseases such as the creation of a unit of reference in the study of occupational diseases and another unit dedicated to the study of respiratory manifestations of patients with immunodeficiencies. He is also coordinator of the Research Unit in Pneumology and, among his discoveries, he found that the asthma epidemic between 1987 and 1987 in Barcelona was caused by the soya discharge at the port. He has been the chair of prestigious medical societies and the author of more than 240 articles published, many of them on pulmonary fibrosis. Besides Dr. Morell and D. Antoni Dávalos, the ICS has also awarded Dr. Rafel Ramos, researcher of the Primary Health Care Research Center Jordi Gol (IDIAP), during the 6th Research Meeting of the ICS, dedicated to cardiovascular diseases. Dr. David Garcia Dorado, head of the Cardiocirculatory Pathology group has also participated in the session, with a lecture about prevention of ischemic heart diseases and the limitation of its effects in type 2 diabetes.&nbsp; VHIR’s director, Dr. Joan Comella, has also attended the meeting, together with the coordinator of research at the ICS and VHIR’s researcher, Dr. Ricard Pujol, who has presented the excellent results of the seven research centers affiliated to the ICS. More information </td></tr></table>comunica@vhir.org (VHIR)Fri, 6 Jun 2014 00:00:00 GMTResearchers identify a new gene associated with haemorrhagic stroke (05/06/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=130&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0130\2014_0130_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Researchers from the International Stroke Genetics Consortium (ISGC), among them scientists from the Vall d'Hebron Research Institute (VHIR), the Hospital del Mar Medical Research Institute (IMIM), and the Research Foundation MutuaTerrassa (FMT) of the University Hospital MutuaTerrassa (HUMT) have identified a new gene, PMF1, involved in intracerebral haemorrhage. The finding, published in the American Journal of Human Genetics, was possible thanks to the first genome-wide association study (GWAS) on this disease. The researchers performed a meta-analysis on the genetic information obtained in six genome studies carried out in the US and Europe on 1,545 patients of European ancestry with one of the two types of haemorrhagic stroke –lobar and non-lobar– and on 1,481 healthy patients in the control group. Until then, they knew that common genetic variations played a substantial role in the two types of haemorrhagic stroke, but there had never been a study analysing all the genes in such a comprehensive way. Thanks to this work, the researchers have been able to detect a genetic variation in chromosome 1q22 associated with patients with non-lobar haemorrhagic strokes. For Dr Israel Fernández, member of the Neurovascular Diseases research group of the VHIR and head of the Pharmacogenomics and Neurovascular Genetics laboratory of the FMT, “the gene identified (PMF1) may constitute a new risk factor for this disease because it may be related to the breakdown of the blood-brain barrier associated with this type of haemorrhagic stroke”. There is currently no effective treatment for intracerebral stroke, which is the most common type of haemorrhagic stroke. It is not known how the mechanisms that cause its appearance function but it is known that there are many risk factors such as hypertension, amyloid angiopathy and the use of anticoagulant drug treatments. “Furthermore, we have found that different genetic variants are associated with haemorrhages in specific locations in the brain. This can help us to characterise and better understand the different causes of the disease and, therefore, provide us with clues to prevent it or to treat it”, adds Dr Jordi Jiménez, researcher of the IMIM Neurovascular Research Group and a neurologist at the Hospital del Mar. With this discovery, Dr Fernández states that “the door has been opened to the analysis of new metabolic pathways to develop future drugs for this disease and reduce the heavy strain that it places on society”. </td></tr></table>comunica@vhir.org (VHIR)Thu, 5 Jun 2014 00:00:00 GMTVHIR launches 10 grants of 3,000€ to attend the Master in Translational Biomedical Research (03/06/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=128&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0128\2014_0128_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Vall d’Hebron Institute of Research (VHIR) launched this week a new call for grants to attend the Master in Translational Biomedical Research at VHIR, affiliated to the Universitat Autònoma de Barcelona. With the ten grants of 3,000 euros each offered in this edition, VHIR aims to attract international talent and highly qualified students seeking advance research training in all areas of biomedicine and clinical medicine at Vall d’Hebron. Until September 30, applications are open for graduate students enrolled in the master and with a minimum average mark equal to or greater than 2. The aim of the master is to generate excellent young researchers by providing them with the necessary combination of scientific and medical knowledge and skills to contribute successfully to the future of translational medical research. It is addressed to research career, providing access to a PhD programme related to the biomedicine area that the students had previously chosen for their training programme and internship. Requirements More information about the master </td></tr></table>comunica@vhir.org (VHIR)Tue, 3 Jun 2014 00:00:00 GMTDr. Gámez and Dr. Munell participated in a meeting for patients with neuromuscular diseases (03/06/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=129&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0129\2014_0129_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Dr. Josep Gámez, head of the Peripheral Nervous System group at Vall d’Hebron Institute of Research (VHIR), and Dr. Francina Munell, researcher from the Pediatric neurology group, participated in the meeting for patients with neuromuscular diseases organized by the Catalan association of patients with these diseases (ASEM Catalunya) on Saturday at Sant Andreu (Barcelona). Dr. Gamez conducted the workshop entitled “State of the art in health care attention to patients with Steinert dystrophy”, which is the most common muscular dystrophy among adults. He called for the need to establish multidisciplinary units of experts and agreed that medical guidelines are needed as well as psychological services to the families. On the other side, Dr. Munell presented the workshop “State of the art in health care attention to children affected with dystrophinopathies”, with an active participation of the patients’ parents and physiotherapists. In her speech, she explained why the dystrophin deficit causes the Duchenne and Becker diseases, which are the current treatments available and the multidisciplinary health care attention that these patients receive. Besides these workshops, there were discussions and conferences carried out by Catalan researchers and clinicians with deep expertise in these pathologies. </td></tr></table>comunica@vhir.org (VHIR)Tue, 3 Jun 2014 00:00:00 GMTNew drug reduces by 81% the risk of prostate cancer progression (02/06/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=127&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0127\2014_0127_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> An international phase III study, conducted in 1717 patients with metastatic castration-resistant prostate cancer, demonstrates that the use of a new drug, called enzalutamide, before chemotherapy reduces the risk of death caused by the disease and slows down its progression. In this group of patients the tumor does not respond to the hormonal therapies aimed at reducing the male hormones (androgens) that make cancer cells grow. This study demonstrated that the administration of enzalutamide before chemotherapy in patients with metastasis who rarely had symptoms, blocks these hormones, so the start of the chemotherapy can start until 28 months later. Researchers from the Vall d’Hebron University Hospital and the Vall d’Hebron Institute of Oncology (VHIO) participated in this clinical trial, published in The New England Journal of Medicine, that reduced by 81% the progression of the cancer, as compared with 14% among patients receiving placebo. Besides, the new drug is less toxic, with only side effects such as fatigue and hypertension.&nbsp; </td></tr></table>comunica@vhir.org (VHIR)Mon, 2 Jun 2014 00:00:00 GMTDr. Carmen Espejo is awarded with the Merck Serono Research prize in Multiple Sclerosis 2014 (30/05/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=126&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0126\2014_0126_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Dr. Carmen Espejo, researcher of the Clinical Neuroimmunology group at Vall d’Hebron Institute of Research (VHIR) and the Catalan center of Multiple Sclerosis (Cemcat), has been awarded with one of the 7 grants of the Marck Serono Research prize 2014 for the project “Bone morphogenetic proteins as possible biomarkers in multiple sclerosis: expression in injuries and cerebrospinal fluid in patients with multiple sclerosis”, endowed with 25,000€. Bone morphogenetic proteins are thought to inhibit the precursor cells of the oligodendrocytes and differentiate into myelin oligodendrocytes, which are the responsible of creating the substance –myelin– that cover the neurons to enhance the quickly and efficient transmission of the impulses. As multiple sclerosis is an inflammatory and demyelianating disease of the nervous system, Dr. Espejo aims to investigate whether these proteins can be diagnostic and/or prognostic biomarkers of multiple sclerosis. According to Dr. Espejo, “to dispose of such biomarkers is crucial because doctors would select the most effective treatment for each patient”. In other words, patients would receive the treatment with a greater prospect of success and that slow down as much as possible the development of the disease, taking into account the lack of a curative treatment on multiple sclerosis. The Salud 2000 Foundation awarded 7 projects with a total amount of 175,000€ in the ceremony hosted in the National Academy of Medicine in Madrid, in which participated the responsible of the public health care system in Madrid, Francisco Javier Rodríguez, and the director of Instituto de Salud Carlos III, Antoni Andreu. </td></tr></table>comunica@vhir.org (VHIR)Fri, 30 May 2014 00:00:00 GMTDr. Colobran composes a song dedicated to patients with multiple sclerosis (28/05/2014)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=124&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Coinciding with the World Multiple Sclerosis Day, the GAEM foundation of patients with multiple sclerosis launched a song which identifies these patients, with music and lyrics written by Dr. Roger Colobran, researcher of the Immunology group at Vall d’Hebron Institute of Research (VHIR). The Catalan pop-rock group Boxets, in which Dr. Colobran is the guitarist, composed “A prop meu” with the aim to bring closer the problem to the society and to work together to tackle the challenges of both patients and researchers. The Catalan singer Lídia Pujol also participates in this song with the oldest Spanish gospel choir, Cor Carlit Gospel. On this May 28 the Vall d’Hebron University Hospital held an informative meeting on multiple sclerosis, conducted by Cemcat researchers, led by Dr. Xavier Montalban, and researchers from Bellvitge Hospital in Barcelona, Arnau de Vilanova hospital in Lleida and J. Trueta hospital in Girona. In the meeting also participated the responsible of the public health care system in the Catalan government, Dr. Boi Ruiz, the director of health care service at the Servei Català de la Salut, Dr. Àlex Guarga i Rojas, and the executive director of the Multiple Sclerosis Foundation in Catalonia, Rosa Masriera. Cemcat researchers recently presented a study at the 32 congress of the Spanish society of medical radiology which "demonstrated that magnetic resonance imaging in multiple sclerosis has higher diagnosic and prognostic quality than other aspects such as demographic criteria or the study on oligoclonal banding in the cerebrospinal fluid", reported Dr. Àlex Rovira to the newspaper IM Médico<span style=" font-size: 8pt; font-family: 'Verdana', 'Geneva', sans-serif; font-style: normal;</td></tr></table>comunica@vhir.org (VHIR)Wed, 28 May 2014 00:00:00 GMTDr. Rafa Simó talks about the association between diabetes and Alzheimer's disease at BCN-Pittsburgh (27/05/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=123&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0123\2014_0123_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> More than 40 international experts on Alzheimer’s disease participated at the IX Biennial Conference Barcelona-Pittsburg, hosted in La Pedrera building in Barcelona from the 21st to the 23rd of May, to discuss the latest advances and the on-going clinical trials on this disease. Dr. Rafa Simó, head of the Diabetes and Metabolism group at Vall d’Hebron Institute of Research (VHIR), was the chairman of a session on new biological approaches and talked about type 2 diabetes as an accelerator for Alzheimer’s disease. Since the beginning of this year his group leads the European Project “Retinal neurodegeneration in type 2 diabetes as biomarker for&nbsp; Alzheimer’s disease”, funded by the European Foundation for the Study of Diabetes. The tissue of the eye’s retina is very similar to the brain; for that reason, VHIR researchers work with the hypothesis that the neurodegeneration progress advances simultaneously in both locations. In that sense, the project aims to detect early stages of Alzheimer’s disease with just an examination of the retina. At the conference, organized by the ACE Foundation and the Alzheimer Research Center at Pittsburgh University, were also presented the latest clinical trials that include passive immunotherapies based on antibodies, as well as active immunotherapies vaccines developed by Grifols through Araclon Biotech. </td></tr></table>comunica@vhir.org (VHIR)Tue, 27 May 2014 00:00:00 GMTVall d'Hebron presents two innovation projects at the MIHealth (23/05/2014)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2014&num=122&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0122\2014_0122_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The prevention and the quickly integration of high-impact technologies were two of the most discussed points of the MIHealth Management &amp; Clinical Innovation Forum, in which participated more than 700 professionals in May 21 and 22. Vall d’Hebron presented two innovation projects related to this topic: a new continuous automatic bladder irrigation system and a new system of telemedicine and rehabilitation. The project on bladder irrigation led by Montserrat Llinàs, nurse and responsible of Quality and Patients’ Safety at the hospital, was selected finalist of the innovation capsules in the health care sector. The continuous bladder irrigation system is a manual procedure indicated for patients who suffer moderate or severe haematuria, caused by a surgical operation or any disease of the genitourinary system. The project aims to automate this system in order to avoid the complications caused by the current technique such as the obstruction of the urethral catheter due to clots, the reabsorption and the urine infection. On the other hand, the project on telemedicine is a joint initiative of Vall d’Hebron and Vodafone Foundation that consists in a series of personalized exercises that patients must follow in order to improve their mobility after suffering stroke. The system records the exercises to ease the control of the evolution of the treatment and allows programmed videoconferences between doctors and patients. Dr. Marc Ribó, researcher of the Neurovascular Diseases group at Vall d’Hebron Institute of Research (VHIR) presented the project on a poster at the congress. VHIR’s director, Dr. Joan Comella, is member of the scientific committee of this forum which aims to join clinicians and professionals from the fields of healthcare management and industry. </td></tr></table>comunica@vhir.org (VHIR)Fri, 23 May 2014 00:00:00 GMT